论文部分内容阅读
目的观察二肽基肽酶-4抑制剂利格列汀治疗2型糖尿病患者的疗效。方法回顾性分析医院收治的2型糖尿病患者160例的临床资料,根据治疗方法的不同分为观察组和对照组,每组80例。观察组联合应用胰岛素和利格列汀治疗,对照组联合应用胰岛素和瑞格列奈治疗。观察比较2组治疗前后血糖指标及胰岛素相关指标HOMA-IR、HOMA-β的变化情况。结果经治疗,2组空腹血糖、餐后2 h血糖、三酰甘油、血清总胆固醇、糖化血红蛋白数值较治疗前均下降,且观察组下降更为显著(P均<0.05)。经治疗,2组HOMA-IR数值较治疗前降低、HOMA-β数值较治疗前升高,且观察组下降或升高幅度更为显著(P均<0.05)。2组均未出现低血糖反应,也未见其他严重的不良反应。结论对于2型糖尿病的治疗,在胰岛素治疗的基础上应用利格列汀,可在不增加治疗的风险的同时,提高治疗效果,具有较高的应用价值。
Objective To observe the curative effect of dipeptidyl peptidase-4 inhibitor linagliptin on type 2 diabetic patients. Methods The clinical data of 160 patients with type 2 diabetes admitted to the hospital were retrospectively analyzed. According to the different treatment methods, they were divided into observation group and control group, 80 cases in each group. The observation group was treated with insulin and linagliptin, while the control group was treated with insulin and repaglinide. The changes of HOMA-IR and HOMA-β in blood glucose and insulin before and after treatment were observed and compared between the two groups. Results After treatment, the fasting blood glucose, 2 h postprandial blood glucose, triglyceride, total serum cholesterol and glycosylated hemoglobin were decreased in both groups before treatment and more significantly in observation group (all P <0.05). After treatment, the values of HOMA-IR in two groups were lower than those before treatment, and the values of HOMA-β were higher than those before treatment, and the levels of HOMA-β in the two groups were significantly decreased (P <0.05). No hypoglycemia occurred in both groups and no other serious adverse reactions were observed. Conclusions For the treatment of type 2 diabetes, the application of linagliptin on the basis of insulin therapy can improve the therapeutic effect without increasing the risk of treatment, and has high application value.